NJ Bio, Inc., is excited to announce a new strategic collaboration with Charles River Laboratories (CRL) aimed at enhancing ADC manufacturing capabilities and accelerating the journey of ADC programs from the laboratory to the clinic. This partnership combines CRL’s strength in antibody engineering with NJ Bio’s expertise in the development and production of novel linker-payloads, establishing a powerful joint platform for ADC development.
Leveraging both companies’ capabilities, this collaboration seeks to streamline the ADC development process, improve manufacturing outcomes, and deliver high-quality, client-focused results. In 2023, both companies shared the prestigious Best Contract Research Organization (CRO) Award at the 10th World ADC Awards, underscoring their commitment to delivering exceptional services to clients globally. This highlights the industry’s recognition of their expertise and dedication to quality in ADC development and manufacturing.
To read the full press release visit NJ Bio and Charles River Announce a Strategic Alliance to Advance ADC Development and Manufacturing Services | Business Wire